Negara: Indonesia
Bahasa: Bahasa Indonesia
Sumber: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
BUDESONIDE; FORMOTEROL FUMARATE
ASTRAZENECA INDONESIA - Indonesia
BUDESONIDE; FORMOTEROL FUMARATE
160/4.5/DOSIS
SERBUK INHALER
DUS,1 TURBUHALER @ 60 DOSIS
ASTRAZENECA Pharmaceuticals - Sweden
2017-01-31
SYMBICORT ® TURBUHALER ® 160/4.5 MCG/DOSE _budesonide/formoterol _ Inhalation Powder QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose that leaves the mouthpiece) contains budesonide 160 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation. SYMBICORT Turbuhaler 160/4.5 micrograms/inhalation delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler monoproducts, i.e. budesonide 200 micrograms/inhalation (metered dose) and formoterol 6 micrograms/inhalation (metered dose) alternatively labelled as 4.5 micrograms/inhalation (delivered dose). Excipient: Lactose monohydrate 730 micrograms per dose. PHARMACEUTICAL FORM Inhalation powder. White powder THERAPEUTIC INDICATION ASTHMA Symbicort is indicated in adults and adolescents (aged 12 years and older) for the treatment of asthma to relieve symptoms and the reduction of the risk of exacerbations, where the use of inhaled corticosteroids is appropriate. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. POSOLOGY AND METHOD OF ADMINISTRATION ASTHMA SYMBICORT is not intended for the initial management of asthma. The dosage of the components of SYMBICORT is individual and should be adjusted to severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the maintenance dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of beta-agonist and/or corticosteroids by individual inhalers should be prescribed. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be regularly reassessed by their prescriber/health care provider, so that the dosage of SYMBICORT remains optimal Baca dokumen lengkapnya